M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma

Phase 2

Recruiting

Conditions: Sinonasal Melanoma

Interventions: Procedure: Surgical resection

First Posted Date: 2022-09-21

Last Posted Date: 2024-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05546827

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Pirtobrutinib
Drug: Obinutuzumab
Drug: Venetoclax
Drug: Valacyclovir
Drug: Allopurinol

First Posted Date: 2022-09-10

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05536349

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Phase 2

Withdrawn

Conditions: Oropharynx Cancer
Head and Neck Cancer
Squamous Cell Carcinoma

Interventions: Drug: SAR444245
Drug: Cemiplimab

First Posted Date: 2022-09-10

Last Posted Date: 2023-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05535023

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase 2

Recruiting

Conditions: Non Hodgkin Lymphoma
Mantle Cell Lymphoma
Hematologic Malignancy

Interventions: Drug: Pirtobrutinib
Drug: Venetoclax

First Posted Date: 2022-09-06

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05529069

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use

Withdrawn

Conditions: Opioids

Interventions: Other: Opioid Attitudes
Other: Beliefs survey

First Posted Date: 2022-09-06

Last Posted Date: 2024-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05529082

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Phase 1

Withdrawn

Conditions: Refractory T Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia (AML)

Interventions: Drug: Part 1 (STI-6129)
Drug: Part 2 (STI-6129)

First Posted Date: 2022-08-29

Last Posted Date: 2023-08-31

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05519527

Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients

Not Applicable

Recruiting

Conditions: Glioma

Interventions: Behavioral: Questionnaires
Behavioral: Caregiver Assessment

First Posted Date: 2022-08-22

Last Posted Date: 2024-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT05511324

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1

Withdrawn

Conditions: Liver Cancer
Cholangiocarcinoma

Interventions: Drug: Infigratinib
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2022-08-22

Last Posted Date: 2023-08-15

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05510427

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Phase 1

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Ciforadenant

First Posted Date: 2022-08-15

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05501054

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing

Recruiting

Conditions: Prostate Cancer

Interventions: Behavioral: Surveys
Behavioral: Interviews

First Posted Date: 2022-08-11

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT05497024

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy